Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Testicular Neoplasms 1Teratoma 1Sarcoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Ototoxicity 1Osteosarcoma 1Neuroblastoma 1Medulloblastoma 1Liver Neoplasms 1Hepatoblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

daratumumab 3Dexamethasone 3Bortezomib 2sodium thiosulfate 1pomalidomide 1pembrolizumab 1etoposide phosphate 1darlin protein, Dictyostelium 1bosutinib 1Thalidomide 1Restraint, Physical 1Pemetrexed 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Etoposide 1Daunorubicin 1Cytarabine 1Crizotinib 1Cisplatin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has announcements × Restraint, Physical × Clear all
NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Children's Oncology Group

Phase 3 Completed
131 enrolled 18 charts 1 FDA
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡